Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| REGENXBIO Inc.RGNX · Entity 2211 | Director | May 29, 2026 | June 02, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
REGENXBIO Inc.
Report date May 29, 2026 · Filed June 02, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 495,925 |
Reported balance
After 2026-05-29 transaction · row 1
1 source rowRow 1 · 2026-05-29 · Grant · Acquired 9,807 · Balance 495,925 F1: Represents shares of common stock underlying a time-based restricted stock unit award (RSU). 100% of the shares subject to this RSU will vest on May 29, 2027 subject to the continuous service of the recipient to the Issuer. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.01 · Expires 2036-05-29 | Direct | 46,600 |
Reported balance
After 2026-05-29 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-05-29 · Grant · Acquired 46,600 · Balance 46,600 F2: The option will vest May 29, 2027 subject to the continuous service of the optionee to the Issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares of common stock underlying a time-based restricted stock unit award (RSU). 100% of the shares subject to this RSU will vest on May 29, 2027 subject to the continuous service of the recipient to the Issuer.
F2: The option will vest May 29, 2027 subject to the continuous service of the optionee to the Issuer.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 20, 2017 Filed Nov 21, 2017 21:18 UTC | REGENXBIO Inc. RGNX · Entity 2211 | Exercise / conversionCommon Stock | 30,000 | $0.85 | $25,500.00 |
DisclosureSEC source: 0001562180-17-003653 · primarydocument.xml · nonDerivative · entry 1 Mills Kenneth T. · CIK 0001652824 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 128,530 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 20, 2017 Filed Oct 24, 2017 20:18 UTC | REGENXBIO Inc. RGNX · Entity 2211 | SaleCommon Stock | 200 | $33.03 | $6,606.00 |
DisclosureSEC source: 0001562180-17-003313 · primarydocument.xml · nonDerivative · entry 2 Mills Kenneth T. · CIK 0001652824 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 98,530 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F3 · price: This transaction was executed in multiple trades at prices ranging from $33.00 to $33.05. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| October 20, 2017 Filed Oct 24, 2017 20:18 UTC | REGENXBIO Inc. RGNX · Entity 2211 | SaleCommon Stock | 9,800 | $32.61 | $319,578.00 |
DisclosureSEC source: 0001562180-17-003313 · primarydocument.xml · nonDerivative · entry 1 Mills Kenneth T. · CIK 0001652824 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 98,730 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $32.00 to $32.95. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| September 20, 2017 Filed Sep 22, 2017 20:17 UTC | REGENXBIO Inc. RGNX · Entity 2211 | SaleCommon Stock | 100 | $30.05 | $3,005.00 |
DisclosureSEC source: 0001562180-17-002998 · primarydocument.xml · nonDerivative · entry 2 Mills Kenneth T. · CIK 0001652824 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 108,530 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| September 20, 2017 Filed Sep 22, 2017 20:17 UTC | REGENXBIO Inc. RGNX · Entity 2211 | SaleCommon Stock | 9,900 | $29.32 | $290,268.00 |
DisclosureSEC source: 0001562180-17-002998 · primarydocument.xml · nonDerivative · entry 1 Mills Kenneth T. · CIK 0001652824 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 108,630 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $28.90 to $29.85. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| September 05, 2017 Filed Sep 7, 2017 20:29 UTC | REGENXBIO Inc. RGNX · Entity 2211 | SaleCommon Stock | 10,500 | $25.00 | $262,500.00 |
DisclosureSEC source: 0001562180-17-002908 · primarydocument.xml · nonDerivative · entry 1 Mills Kenneth T. · CIK 0001652824 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 118,530 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| August 25, 2017 Filed Aug 29, 2017 20:23 UTC | REGENXBIO Inc. RGNX · Entity 2211 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 23,530 | $0.00 Strike: $0.85 | $0.00 |
DisclosureSEC source: 0001562180-17-002801 · primarydocument.xml · derivative · entry 2 Mills Kenneth T. · CIK 0001652824 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 559,670 Underlying: Common Stock · 23,530 shares Expires 2024-09-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The previously granted option, representing a right to purchase a total of 708,200 shares, became exercisable as follows: 474,490 of the shares subject to the option are initial shares ("Initial Shares") and 233,710 of the shares subject to the option are contingent shares ("Contingent Shares"). 120,394 of the Initial Shares vested on September 17, 2014, 88,524 of the Initial Shares vested on September 17, 2015 and an additional 7,377 of the Initial Shares vest upon each month of continuous service to the Company thereafter. 25% of the Contingent Shares were deemed vested as of September 17, 2014 on January 13, 2015 due to a subsequent event. The remainder of the Contingent Shares vest over four years of service following September 17, 2014, with 25% of the remaining 75% of Contingent Shares having vested on September 17, 2015 and the remaining Contingent Shares vesting in 36 equal monthly installments thereafter. Read SEC document |
| August 25, 2017 Filed Aug 29, 2017 20:23 UTC | REGENXBIO Inc. RGNX · Entity 2211 | Exercise / conversionCommon Stock | 23,530 | $0.85 | $20,000.50 |
DisclosureSEC source: 0001562180-17-002801 · primarydocument.xml · nonDerivative · entry 1 Mills Kenneth T. · CIK 0001652824 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 129,030 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 21, 2017 Filed Aug 23, 2017 20:21 UTC | REGENXBIO Inc. RGNX · Entity 2211 | SaleCommon Stock | 6,500 | $20.05 | $130,325.00 |
DisclosureSEC source: 0001562180-17-002782 · primarydocument.xml · nonDerivative · entry 1 Mills Kenneth T. · CIK 0001652824 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 105,500 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $19.95 to $20.20. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| July 20, 2017 Filed Jul 24, 2017 20:19 UTC | REGENXBIO Inc. RGNX · Entity 2211 | SaleCommon Stock | 6,500 | $18.66 | $121,290.00 |
DisclosureSEC source: 0001562180-17-002501 · primarydocument.xml · nonDerivative · entry 1 Mills Kenneth T. · CIK 0001652824 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 112,000 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $18.25 to $18.95. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| June 20, 2017 Filed Jun 22, 2017 20:25 UTC | REGENXBIO Inc. RGNX · Entity 2211 | SaleCommon Stock | 896 | $20.16 | $18,063.36 |
DisclosureSEC source: 0001562180-17-002307 · primarydocument.xml · nonDerivative · entry 2 Mills Kenneth T. · CIK 0001652824 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 118,500 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F3 · price: This transaction was executed in multiple trades at prices ranging from $20.05 to $20.30. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| June 20, 2017 Filed Jun 22, 2017 20:25 UTC | REGENXBIO Inc. RGNX · Entity 2211 | SaleCommon Stock | 5,604 | $19.60 | $109,838.40 |
DisclosureSEC source: 0001562180-17-002307 · primarydocument.xml · nonDerivative · entry 1 Mills Kenneth T. · CIK 0001652824 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 119,396 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $19.00 to $19.95. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| April 24, 2017 Filed Apr 27, 2017 01:02 UTC | REGENXBIO Inc. RGNX · Entity 2211 | SaleCommon Stock | 1,395 | $21.40 | $29,853.00 |
DisclosureSEC source: 0000899243-17-010933 · doc4.xml · nonDerivative · entry 2 Mills Kenneth T. · CIK 0001652824 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,000 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F3 · price: This transaction was executed in multiple trades at prices ranging from $21.40 to $21.425. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| April 24, 2017 Filed Apr 27, 2017 01:02 UTC | REGENXBIO Inc. RGNX · Entity 2211 | SaleCommon Stock | 14,045 | $20.94 | $294,102.30 |
DisclosureSEC source: 0000899243-17-010933 · doc4.xml · nonDerivative · entry 1 Mills Kenneth T. · CIK 0001652824 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 126,395 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $20.40 to $21.35. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| January 04, 2017 Filed Jan 6, 2017 22:01 UTC | REGENXBIO Inc. RGNX · Entity 2211 | GrantStock Option (Right to Buy) · Derivative | 130,000 | $0.00 Strike: $19.50 | $0.00 |
DisclosureSEC source: 0000899243-17-000697 · doc4.xml · derivative · entry 1 Mills Kenneth T. · CIK 0001652824 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 130,000 Underlying: Common Stock · 130,000 shares Expires 2027-01-03 F1 · derivative.exercise_date: 25% of the shares subject to this option shall vest after 12 months of continuous service with the Issuer. The balance will vest in equal monthly installments over the 36 months following 1/4/2018 while the optionee provides continuous service to the Issuer. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.